AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02236897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET Scanning
Study NCT00860769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASHA LIFE
Description: 6-session education groups discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills
Study NCT00860769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: USUAL Care
Description: 3 session educational group focusing on HIV prevention, anti-retroviral therapy and parenting
Study NCT02248233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine
Description: Jiangsu Jichuan Pharmaceutical Co., Ltd., Jiangsu Province, China
Study NCT02248233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline + citicoline
Description: physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
Study NCT03789370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Maintanance of general anaesthesia with propofol
Study NCT03789370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Maintainance of general anaesthesia with sevoflurane.
Study NCT02695186 — intervention group
Intervention type: PROCEDURE
Intervention: Gastroscopy
Description: Gastroscopy and biopsies, as well as blood sample collection
Study NCT00798408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fluid Supplement
Description: The fluid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation\*1.5 activity factor, volume, and amount and type of macronutrients
Study NCT00798408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Solid Supplement
Description: The solid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation\*1.5 activity factor, volume, and amount and type of macronutrients
Study NCT01251055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlyT-1 inhibitor-1
Description: GlyT-1 inhibitor-1(500) 4# BID
Study NCT01251055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch
Study NCT06638749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Administration of tranexamic acid
Study NCT06638749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administration of normal saline
Study NCT06261138 — intervention group
Intervention type: DRUG
Intervention: Transarterial chemoembolization
Description: A 5-French RH catheter was then introduced to the celiac artery, superior mesenteric and artery common hepatic artery for angiography to determine tumor location, quantity, size, and vascularity. After confirmation by C-arm cone-beam computed tomography (CBCT), chemoembolization was administered by superselective catheterization of the branches of the tumor-feeding arteries using a 2.8-French coaxial microcatheter. For cTACE, oxaliplatin, raltitrexed and an emulsion containing idarubicin and ethiodized oil were infused for over 20 minutes, followed by combined embolization with blank embolic microspheres. For DEB-TACE, DC/LC Beads® (Biocompatibles, Farnham, Surrey, UK), as drug carriers and embolic materials, were loaded with doxorubicin hydrochloride and mixed with nonionic contrast medium. Real-time assessment of embolization was performed with the assistance of CBCT.
Study NCT06261138 — intervention group
Intervention type: OTHER
Intervention: Systemic treatment
Description: sorafenib (Bayer HealthCare, Berlin, Germany), lenvatinib (Eisai, Tokyo, Japan), apatinib (Hengrui Pharmaceuticals, Lianyungang, China) and donafenib (Zelgen Biopharmaceuticals, Suzhou, China), while a minority of patients received bevacizumab (Innovent Biologics, Suzhou, China).~sintilimab (Innovent Biologics, Suzhou, China), toripalimab (Junshi Biosciences, Suzhou, China), camrelizumab (Hengrui Pharmaceuticals, Lianyungang, China), tislelizumab (BeiGene, Shanghai, China), pembrolizumab (Merck Sharp \& Dohme, NewJersey, USA), nivolumab (Bristol Myers Squibb, New York, USA), atezolizumab (Roche, Basel, Switzerland) and envafolimab (Alphamab Biopharmaceuticals, Suzhou, China).
Study NCT02680847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02
Description: Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
Study NCT05098821 — intervention group
Intervention type: OTHER
Intervention: not applicable, observational study
Description: Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
Study NCT03687671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy
Description: Animal-assisted occupational therapy, animal-assisted physiotherapy and animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
Study NCT03687671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Speech therapy, occupational therapy or physiotherapy
Study NCT03175003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Product
Description: Each food product will provide similar calories, but a different micro- and macro-nutrient composition
Study NCT03175003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product
Description: Each food product will provide similar calories, but a different micro- and macro-nutrient composition
Study NCT04409431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular chemical Ablation of Adrenal Gland
Description: Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol
Study NCT01454960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDS Order Sets: Suggested Alternatives
Description: Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
Study NCT00914680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic seizure therapy
Description: antidepressant treatment with MST
Study NCT03516825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musical Neglect Training
Description: MNT uses musical exercises which are structured in pitch, time and tempo, and musical equipment (tone bars, keyboards, drums) configures to focus attention to the neglect visual field.
Study NCT01528033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Assisted Closure®
Description: Vacuum Assisted Closure® (V.A.C.®) Therapy within a maximum study treatment time of 42 days.~VAC® Therapy Systems used within the trial are ActiV.A.C.®, InfoV.A.C.®, V.A.C. Freedom®, V.A.C. Via® and VAC Ulta®. All used systems are equally eligible for the treatment of subcutaneous abdominal wounds and should be used according to availability and local preferences within the trial site.~Systems differ regarding user surface and display and processing of data. For the treatment of subcutaneous abdominal wounds the V.A.C.® Granufoam Dressing (size medium and big) is recommended.
Study NCT01528033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard conventional wound therapy
Description: Standard conventional wound therapy (SCWT) according to institutional clinical standards within a maximum study treatment time of 42 days
Study NCT03388931 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Increased radiation therapy dose
Study NCT03388931 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard-of-care chemotherapy with treatment regimen to be determined by the treating physician
Study NCT01923987 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short Course Radiotherapy
Description: Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days
Study NCT01923987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: * Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1~* Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1~* Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2~* 5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).~* Bevacizumab 5 mg/kg IV over 90 mins on Day 1~* Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.~* FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses~* Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)
Study NCT01923987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Surgery
Description: If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).
Study NCT01089673 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: retrospective data collection
Study NCT04459624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spina Plane Block
Description: Group E (ESP block) will be applied 20 ml of % 0.25 bupivacaine between the erector spina muscle and transverse process at the 8th thoracic level. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
Study NCT04459624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block 2
Description: Group Q (QLB2 block) lumbar interfacial triangle (LIFT) will be applied 20 ml of % 0.25 bupivacaine. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
Study NCT00590889 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Artificial Mechanical Heart Valve
Description: Both arms used market released mechanical heart valves in accordance with approved labeling
Study NCT01854996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: 450mg
Study NCT03839498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.~Starting dose level 1: 5 mg every morning; 5 mg every evening. Dose level 2: 7 mg every morning; 7 mg every evening. Dose level 3: 10 mg every morning; 10 mg every evening. Dose level -1: 3 mg every morning; 3 every evening. Dose level -2: 2 mg every morning; 2 mg every evening.~Axitinib is supplied as 1 and 5-mg tablets and is administered orally twice a day with or without food, each morning and evening (i.e., every 12 hours). Axitinib will be given as self-administered.
Study NCT02643173 — intervention group
Intervention type: OTHER
Intervention: Volatile anesthetics
Study NCT02643173 — intervention group
Intervention type: OTHER
Intervention: Intravenous anesthetics
Study NCT01879514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herb Prescription Granule plus prednisone
Description: Chinese Herb Prescription Granule includes ZiBuGanShen Granule and BuShenTongLuo Granule
Study NCT01879514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
Study NCT03023462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oksykodonhydroklorid
Description: Oksykodonhydroklorid, 5 - 10 mg intravenously or orally postoperatively to reduce pain. Repetition until effect.
Study NCT03023462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron and Droperidol
Description: When nausea and vomiting: Ondansetron 4mg and droperidol 0,625 mg intravenously
Study NCT03023462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic for the block
Study NCT01180101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and exercise
Description: This group will follow a hypocaloric diet and supervised exercise training for 12 weeks.
Study NCT01180101 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric Surgery
Description: Patients will undergo bariatric surgery
Study NCT03993470 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Short foot excercise for intrinsec muscles of the foot
Description: to examine the effects of the SFE compared to a placebo exercise in the foot posture index after a daily period of 4 weeks.
Study NCT03967925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: IV infusion 1g x 2
Study NCT03967925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 20mg prednisolone tapering dose
Study NCT03967925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: 20mg prednisolone tapering dose
Study NCT04519450 — intervention group
Intervention type: DEVICE
Intervention: Mindray TE7 ultrasound machine
Description: The study was performed using a Mindray TE7 ultrasound machine with the depth of the linear probe at 70 mm and gain of 90 dB; settings remained unchanged during the study. Measurements of the right m. sternocleidomastoideus, the right m. trapezius, and the right upper leg were taken, with the final value being the average of three measurements for each. The probe was set at the musculoskeletal ultrasound setting.
Study NCT01129778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zegerid (proton pump inhibitor)
Study NCT01129778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bravo pH monitoring
Study NCT01467700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon SL
Description: Ramelteon SL tablets
Study NCT01467700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets
Study NCT03794947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning
Description: Induced ischaemia to a limb by inflating pressure cuffs around arms or legs to above systolic pressures (mmHg).
Study NCT03794947 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: The sham intervention will inflate pressure cuffs to much lower levels for the same number of cycles.
Study NCT03880422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive diet plan
Study NCT03880422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend educational meeting
Study NCT00936650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
Study NCT00936650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet
Description: Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
Study NCT03622983 — intervention group
Intervention type: OTHER
Intervention: collection of sample and data
Description: Recovery of surgical waste during surgery planned in the current care and clinical data collection
Study NCT01878448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Study NCT03962647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-Week Ketogenic Diet
Description: 2-Week Ketogenic Diet in Combination with Letrozole
Study NCT03962647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg taken once daily by mouth
Study NCT03962647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg taken once daily by mouth
Study NCT03653546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3759
Description: AZD3759 200mg PO BID.
Study NCT03653546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: SoC EGFRTKI Erlotinib 150 mg PO Q.D
Study NCT03653546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: SoC EGFRTKI Gefitinib 250 mg PO Q.D
Study NCT00835549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir for oral suspension 250 mg/5mL
Description: 1 x 250 mg/5mL, single-dose non-fasting
Study NCT00835549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMNICEF® for oral suspension 250 mg/5mL
Description: 1 x 250 mg/5mL, single-dose non-fasting
Study NCT02886962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: No oral anticoagulation
Description: No oral anticoagulation, and no monitoring of the INR.
Study NCT02886962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral anticoagulation with vitamin K antagonists
Description: Vitamin K antagonist prescription with INR target between 2 and 3 as recommended in the guidelines.~Administration once daily or at the end of each dialysis session, according to the nephrologist choice.~INR monitoring at least once per week
Study NCT04049214 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meditation
Description: Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
Study NCT04606290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2matic HOT
Description: Automated oxygen titration with O2matic HOT
Study NCT04606290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen concentrator
Description: Fixed dose oxygen flow from concentrator
Study NCT03880422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete exercise program
Study NCT03880422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03880422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04204408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
Study NCT04204408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Mim8)
Description: Mim8 placebo administered subcutaneously (s.c., under the skin)
Study NCT04166487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: predetermined dose, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
Study NCT04166487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEMETREXED
Description: administered per standard practice, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
Study NCT04166487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARBOPLATIN
Description: administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
Study NCT04166487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACLITAXEL
Description: administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
Study NCT04166487 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: InVision
Description: Plasma draw for clinical test performed at C1D1 and C2D1; plasma draw for research testing performed at other timepoints per protocol.
Study NCT03732820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 300 mg (2 x 150 milligrams (mg) tablets) twice daily
Study NCT03732820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: 1000 milligrams (mg) once daily
Study NCT03732820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: abiraterone acetate
Description: 1000 milligrams (mg) once daily
Study NCT03960710 — intervention group
Intervention type: OTHER
Intervention: Anonymized CT examinations
Description: The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.
Study NCT03960710 — intervention group
Intervention type: OTHER
Intervention: Training (1)
Description: An initial training phase of the artificial intelligence network will be carried out :~- Segmentation of the livers of a first part of the CT examination, by an intern of the Lyon hospitals